A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...

The Lehigh Valley Planning Commission made recommendations on transportation, wetlands protection and sustainable building ...

UPPER MACUNGIE TOWNSHIP, Pa. - The Lehigh Valley Planning Commission is taking a closer look at the proposed Eli Lily ...

The Lehigh Valley Planning Commission, an advisory body, will share with Upper Macungie its review of Eli Lilly’s plans for a ...

With the success of GLP-1-based drugs, pharmaceutical companies are aggressively pursuing next-generation versions that could provide patients with more refined options for controlling diabetes and ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly will announce additional data at a conference later this year. Credit: Michael Vi / Shutterstock.com. (Michael Vi / ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% ...

Eli Lilly's (NYSE: LLY) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% and 175%, respectively, in 2025. It's ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up. According to lead investigator Dr. Julio Rosenstock, Lilly’s pill ...

It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...

Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...